Genetic polymorphisms of the human MDR1 drug transporter

被引:234
作者
Schwab, M
Eichelbaum, M
Fromm, MF
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Univ Tubingen Hosp, Div Clin Pharmacol, D-72076 Tubingen, Germany
关键词
P-glycoprotein; ABC transporter; pharmacogenetics; drug disposition; pharmacogenomics;
D O I
10.1146/annurev.pharmtox.43.100901.140233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoprotein is an ATP-dependent efflux pump that contributes to the protection of the body from environmental toxins. It transports a huge variety of structurally diverse compounds. P-glycoprotein is involved in limiting absorption of xenobiotics from the gut lumen, in protection of sensitive tissues (brain, fetus, testis), and in biliary and urinary excretion of its substrates. P-glycoprotein can be inhibited or induced by xenobiotics, thereby contributing to variable drug disposition and drug interactions. Recently, several SNPs have been identified in the MDR1 gene, some of which can affect P-glycoprotein expression and function. Potential implications of MDR1 polymorphisms for drug disposition, drug effects, and disease risk are discussed.
引用
收藏
页码:285 / 307
页数:23
相关论文
共 110 条
[41]  
Ito T, 1997, J PHARMACOL EXP THER, V282, P955
[42]   INTERACTION OF DRUGS WITH P-GLYCOPROTEIN IN BRAIN CAPILLARIES [J].
JETTE, L ;
MURPHY, GF ;
LECLERC, JM ;
BELIVEAU, R .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (10) :1701-1709
[43]   SURFACE GLYCOPROTEIN MODULATING DRUG PERMEABILITY IN CHINESE-HAMSTER OVARY CELL MUTANTS [J].
JULIANO, RL ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1976, 455 (01) :152-162
[44]   TRANSPORT OF CELIPROLOL ACROSS HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS - MEDIATION OF SECRETION BY MULTIPLE TRANSPORTERS INCLUDING P-GLYCOPROTEIN [J].
KARLSSON, J ;
KUO, SM ;
ZIEMNIAK, J ;
ARTURSSON, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1009-1016
[45]  
Kerb R., 2001, Pharmacogenomics Journal, V1, P204
[46]   The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].
Kim, RB ;
Fromm, MF ;
Wandel, C ;
Leake, B ;
Wood, AJJ ;
Roden, DM ;
Wilkinson, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :289-294
[47]  
Kim RB, 1999, PHARMACEUT RES, V16, P408
[48]   Identification of functionally variant MDR1 alleles among European Americans and African Americans [J].
Kim, RB ;
Leake, BF ;
Choo, EF ;
Dresser, GK ;
Kubba, SV ;
Schwarz, UI ;
Taylor, A ;
Xie, HG ;
McKinsey, J ;
Zhou, S ;
Lan, LB ;
Schuetz, JD ;
Schuetz, EG ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :189-199
[49]   Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system [J].
Kimchi-Sarfaty, C ;
Gribar, JJ ;
Gottesman, MM .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :1-6
[50]   P-GLYCOPROTEIN GENE (MDR1) CDNA FROM HUMAN ADRENAL - NORMAL P-GLYCOPROTEIN CARRIES GLY185 WITH AN ALTERED PATTERN OF MULTIDRUG RESISTANCE [J].
KIOKA, N ;
TSUBOTA, J ;
KAKEHI, Y ;
KOMANO, T ;
GOTTESMAN, MM ;
PASTAN, I ;
UEDA, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (01) :224-231